Next Article in Journal
Plasmodial Transcription Factors and Chromatin Modifiers as Drug Targets
Previous Article in Journal
Erythrocyte Folyl Polyglutamate Synthetase Activity Profiling as a Potential Tool for the Prediction of Methotrexate Efficacy and Toxicity in Rheumatoid Arthritis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Future Pharmacology
Volume 3
Issue 4
10.3390/futurepharmacol3040050
futurepharmacol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Considerations of Nystatin Roll in Oral Candidiasis Scenario and the COVID-19 Pandemic—A Review

by
Michelle Maria Gonçalves Barão de Aguiar
,
Renata Miliani Martinez
,
André Rolim Baby
* and
Cristina Helena dos Reis Serra
Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-900, Brazil
*
Author to whom correspondence should be addressed.
Future Pharmacol. 2023, 3(4), 834-845; https://doi.org/10.3390/futurepharmacol3040050
Submission received: 29 August 2023 / Revised: 27 September 2023 / Accepted: 1 November 2023 / Published: 7 November 2023
Browse Figure
Versions Notes

Abstract

Oral candidiasis is an opportunistic infection usually related to predisposing factors. Oral manifestations in patients affected by COVID-19 have been reported, as the oral mucosa is the gateway to this viral infection. Xerostomia, as well as other oral symptoms, are predisposing factors for the emergence of oral candidiasis after the COVID-19 pandemic. It is a common pathology, but fatal if left untreated. Nystatin (NYS) is the drug of first choice in the treatment of oral candidiasis. Herein, we reviewed the epidemiology of oral candidiasis and its treatments, focusing on the mechanism of action, dosage forms, and NYS efficacy. NYS is an effective drug against oral candidiasis and belongs to Class IV of the biopharmaceutical classification system; however, its low solubility and low permeability may compromise its availability in the oral cavity and, consequently, its pharmacological action. Future perspectives to overcome drug limitations were also addressed and discussed in our review.
Keywords: nystatin; oral candidiasis; COVID-19; pharmaceutical dosage forms nystatin; oral candidiasis; COVID-19; pharmaceutical dosage forms

Share and Cite

MDPI and ACS Style

de Aguiar, M.M.G.B.; Martinez, R.M.; Baby, A.R.; Serra, C.H.d.R. Considerations of Nystatin Roll in Oral Candidiasis Scenario and the COVID-19 Pandemic—A Review. Future Pharmacol. 2023, 3, 834-845. https://doi.org/10.3390/futurepharmacol3040050

AMA Style

de Aguiar MMGB, Martinez RM, Baby AR, Serra CHdR. Considerations of Nystatin Roll in Oral Candidiasis Scenario and the COVID-19 Pandemic—A Review. Future Pharmacology. 2023; 3(4):834-845. https://doi.org/10.3390/futurepharmacol3040050

Chicago/Turabian Style

de Aguiar, Michelle Maria Gonçalves Barão, Renata Miliani Martinez, André Rolim Baby, and Cristina Helena dos Reis Serra. 2023. "Considerations of Nystatin Roll in Oral Candidiasis Scenario and the COVID-19 Pandemic—A Review" Future Pharmacology 3, no. 4: 834-845. https://doi.org/10.3390/futurepharmacol3040050

APA Style

de Aguiar, M. M. G. B., Martinez, R. M., Baby, A. R., & Serra, C. H. d. R. (2023). Considerations of Nystatin Roll in Oral Candidiasis Scenario and the COVID-19 Pandemic—A Review. Future Pharmacology, 3(4), 834-845. https://doi.org/10.3390/futurepharmacol3040050

Article Metrics

Back to TopTop